News headlines about Proteostasis Therapeutics (NASDAQ:PTI) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Proteostasis Therapeutics earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned news stories about the company an impact score of 44.9178465682105 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment’s rankings:
- Proteostasis Therapeutics, Inc. (PTI) – 52-Week New High Stock to Track (thestocksnews.com)
- Investor’s Roundup (PEG Analysis) – Proteostasis Therapeutics (NASDAQ:PTI) (nasdaqjournal.com)
- Technical news From Proteostasis Therapeutics, Inc. (PTI) (wallstreetmorning.com)
- Proteostasis Therapeutics, Inc. (PTI): Keep tabs on Active Stock: (stockquote.review)
- Proteostasis Therapeutics, Inc. (PTI) expected to achieve -13.60% earnings growth for this year (wallstreetinvestorplace.com)
Several research analysts recently weighed in on the company. ValuEngine raised Proteostasis Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, March 28th. Zacks Investment Research upgraded Proteostasis Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 14th. Finally, Royal Bank of Canada started coverage on Proteostasis Therapeutics in a research note on Friday, March 9th. They set an “outperform” rating and a $11.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. Proteostasis Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $13.45.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Proteostasis Therapeutics (PTI) Stock Price” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/3382393/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-proteostasis-therapeutics-pti-stock-price.html.
Proteostasis Therapeutics Company Profile
Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study.
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.